BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Intec Pharma Ltd. Breakthrough In Gastric Retention: Accordion Pill Doubles Drug Absorption


10/19/2005 5:09:19 PM

MIAMI, Florida, June 21 /PRNewswire/ -- Intec Pharma Ltd. (Israel) announced today the successful results of a clinical trial using a drug marker on healthy volunteers at the Sheba Medical Center in Israel. The results validate the company's proprietary Accordion Pill, a novel gastroretentive platform that targets drugs that must be absorbed by the body in what is known as the Narrow Absorption Window, the intestine segment below the stomach.

The study used Riboflavin (vitamin B2) as a model active ingredient to demonstrate the unique capability of the Accordion Pill formulation to prolong absorption of pharmaceuticals into the blood. The prolonged absorption enables greater bioavailability while reducing dosage and side effects. Many important pharmaceutical compounds are limited in their therapeutic action because insufficient amounts are absorbed into the body through this area,

"The study results confirm Accordion Pill as the first gastroretentive formulation to maintain controlled release and absorption of a drug for more than 6 hours following a low calorie meal," said Efi Cohen-Arazi, CEO of Intec Pharma. "This is a major milestone, positioning Intec Pharma as a leader in the gastric retention field with a platform technology that can improve the bioavailability of drugs in an estimated $50 billion market," he added.

The study was based on cross-over data from thirteen healthy volunteers who received alternate 75 mg. doses of Accordion Pill Riboflavin and regular immediate release Riboflavin following a low calorie meal (280 calories).

The study results showed that the Riboflavin Accordion Pill was retained in the stomach and continued to release Riboflavin to its absorption sites for significantly longer periods of time than regular Riboflavin. The stomach retention time for Accordion Pill Riboflavin was more than 6 hours compared to less than 2 hours with regular Riboflavin; the absorption time for Accordion Pill Riboflavin was 8 hours compared to 3 hours for regular Riboflavin. As a result, the total amount of Riboflavin absorbed by the body was 100 percent greater when the Accordion Pill was used than when it was not.

The study results were presented by Prof. Amnon Hoffman of the Hebrew University at the 32nd annual meeting of the Controlled Release Society in Miami, Florida. Prof. Hoffman together with Prof. Michael Friedman is co-developer of the Accordion Pill and a member of the Intec Pharma Scientific Advisory Board.

About Intec Pharma Ltd.

Intec Pharma Ltd., a drug development company based in Jerusalem, Israel, has developed an advanced oral drug delivery system, based on its proprietary gastric-retention platform technology (The Accordion Pill). This unique solution is non-drug specific, and designed to significantly improve pharmacokinetics, efficacy and patient compliance of a wide range of drugs. This technology offers a new competitive edge in the area of oral drug development and for product life cycle management.

For more information visit www.intecpharma.com or contact Etti Lavian +972-2-586-4657 ext. 101 etti@intecpharma.com Intec Pharma Ltd. 10 Hartom St Jerusalem 91450, Israel

Intec Pharma Ltd.

CONTACT: For more information visit www.intecpharma.com or contact: EttiLavian, +972-2-586-4657 ext. 101, etti@intecpharma.com, Intec Pharma Ltd.,10 Hartom St, Jerusalem 91450, Israel



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES